Perioperative statin therapy and renal outcomes after major vascular surgery: a propensity-based analysis.
OBJECTIVE
To evaluate how the presence and timing of statin therapy affect perioperative renal outcomes after major vascular surgery.


METHODS
Retrospective cohort study.


METHODS
Surgical intensive care unit at a single academic medical center.


METHODS
Patients undergoing major vascular surgery between July 2004 and October 2005.


RESULTS
The presence and timing of perioperative statin administration and the propensity for receiving such therapy were noted. Renal outcomes, lengths of stay, and mortality were reviewed. One hundred fifty-one procedures were performed. Eighty-nine patients (59%) received statin therapy. There was no evidence for renal protection with perioperative statin therapy (Delta creatinine 0.2 mg/dL v 0.2 mg/dL, p = 0.41; acute renal injury/acute renal failure 8% v 6%, p = 1.00; renal replacement therapy 3% v 3%, p = 1.00; all statin v no statin, respectively). With the possible exception of early reinstitution of statin therapy in chronic statin users, subgroup analyses failed to confirm an association between statin timing and prevention of postoperative renal dysfunction.


CONCLUSIONS
In the present investigation, neither the presence nor timing of perioperative statin therapy was associated with improved renal outcomes in patients undergoing a range of major vascular procedures. A possible exception is early postoperative reinitiation of statin therapy in chronic statin users. The discrepant results of available literature preclude a definitive statement on the use of statin therapy as a means of preventing postoperative renal dysfunction. An adequately powered prospective trial is needed before advocating the routine use of statin therapy for perioperative renal protection.
Kor
Daryl J
DJ
Department of Anesthesiology, Division of Critical Care, Mayo Clinic College of Medicine, Rochester, MN, USA.
Brown
Michael J
MJ
Iscimen
Remzi
R
Brown
Daniel R
DR
Whalen
Francis X
FX
Roy
Tuhin K
TK
Keegan
Mark T
MT
D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D007902:Length of Stay / Q000639:trends; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care / Q000379:methods*; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D012189:Retrospective Studies; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors